The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study
Makaleler > Tam Makale · 2021
Yazarlar: Atilla Soran, Lutfi Dogan, Arda Isik, Serdar Ozbas, Didem Can Trabulus, Umut Demirci, Hasan Karanlik, AYKUT SOYDER, AHMET DAĞ, Ahmet Bilici, Mutlu Dogan, Hande Koksal, MEHMET ALİ NAHİT ŞENDUR, Mehmet Ali Gulcelik, GÖKTÜRK MARALCAN, Neslihan Cabioglu, Levent YENİAY, Zafer Utkan, TURGAY ŞİMŞEK, Nuri Karadurmus, Gul Daglar, Birol Yildiz, Cihan URAS, Mustafa Tukenmez, Ahmet Yildirim, Suat Kutun, Cihangir Ozaslan, Niyazi Karaman, Müfide Nuran AKÇAY, Osman Toktaş, EFE SEZGİN
Annals of Surgical Oncology, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2021, cilt 28, ss 5048-5057
DOI: 10.1245/s10434-021-09621-8
Özet
Background More evidence shows that primary surgery for de novo metastatic breast cancer (BC) prolongs overall survival (OS) in selected cases. The aim of this study was to evaluate the role of locoregional treatment (LRT) in BC patients with de novo stage IV bone only metastasis (BOM). Methods The prospective, multicenter registry study BOMET MF14-01 was initiated in May 2014. Patients with de novo stage IV BOM BC were divided into two groups: those receiving systemic treatment (ST group) and those receiving LRT (LRT group). Patients who received LRT were further divided into two groups: ST after LRT (LRT + ST group) and ST before LRT (ST + LRT group). Results We included 505 patients in this study; 240 (47.5%) patients in the ST group and 265 (52.5%) in the LRT group. One hundred and thirteen patients (26.3%) died in the 34-month median follow-up, 85 (35.4%) in the ST group and 28 (10.5%) in LRT group. Local progression was observed in 39 (16.2%) of the patients in the ST group and 18 (6.7%) in the LRT group (p = 0.001). Hazard of death was 60% lower in the LRT group compared with the ST group (HR 0.40, 95% CI 0.30-0.54, p < 0.0001). Conclusion In this prospectively maintained registry study, we found that LRT prolonged survival and decreased locoregional recurrence in the median 3-year follow-up. Timing of primary breast surgery either at diagnosis or after ST provided a survival benefit similar to ST alone in de novo stage IV BOM BC patients.